UNICYCIVE THERAPEUTICS, INC. Preferred Stock Dividends and Other Adjustments
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Preferred Stock Dividends and Other Adjustments of $1.09 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsAndOtherAdjustments · last filed 2026-03-30
- UNICYCIVE THERAPEUTICS, INC. preferred stock dividends and other adjustments for the quarter ending 2024-12-31 was $0.00.
- UNICYCIVE THERAPEUTICS, INC. preferred stock dividends and other adjustments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. preferred stock dividends and other adjustments for the quarter ending 2024-06-30 was $887.00K, a 47.10% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. preferred stock dividends and other adjustments for the quarter ending 2024-03-31 was $208.00K, a 8.33% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. preferred stock dividends and other adjustments for fiscal 2024 was $1.09M, a 26.30% increase from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. preferred stock dividends and other adjustments for fiscal 2023 was $867.00K.
| Period end | Preferred Stock Dividends and Other Adjustments 3 month | Preferred Stock Dividends and Other Adjustments 6 month | Preferred Stock Dividends and Other Adjustments 9 month | Preferred Stock Dividends and Other Adjustments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $887.00K derived: sum of 3 quarters · filed 2026-03-30 | $1.09M 10-K · filed 2026-03-30 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $887.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.09M 10-Q · filed 2025-11-12 | $1.09M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $887.00K 10-Q · filed 2025-08-14 | $1.09M 10-Q · filed 2025-08-14 | $1.09M derived: sum of 3 quarters · filed 2025-08-14 | $1.17M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $208.00K 10-Q · filed 2024-05-13 | $208.00K derived: sum of 2 quarters · filed 2025-03-31 | $280.00K derived: sum of 3 quarters · filed 2025-03-31 | $883.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $72.00K derived: sum of 2 quarters · filed 2025-03-31 | $675.00K derived: sum of 3 quarters · filed 2025-03-31 | $867.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $72.00K 10-Q · filed 2023-11-14 | $675.00K derived: sum of 2 quarters · filed 2024-08-14 | $867.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $603.00K 10-Q · filed 2024-08-14 | $795.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $192.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |